Summary

The regenerative therapies market is on a significant growth trajectory, with its value projected to rise from $11.44 billion in 2024 to $21.53 billion by 2031, reflecting a robust CAGR of 9.40%. These cutting-edge therapies aim to restore the function of damaged tissues or organs in patients suffering from chronic conditions or severe injuries, heralding a new era in medical treatment. The market's expansion is further accelerated by the increasing demand for innovative solutions that address previously unmet therapeutic needs across various medical disciplines.

Oncology Sector Drives Market Momentum

Within the regenerative therapies market, the oncology sector is emerging as a significant growth driver. Cancer, one of the most devastating diseases globally, continues to pose a formidable challenge in patient care and survival. Despite the availability of conventional treatments like surgery, chemotherapy, and radiation, the high mortality rate associated with cancer remains a critical issue. Regenerative therapies, such as tissue engineering, cell therapy, and gene therapy, are gaining prominence as potential alternatives to traditional treatments, offering renewed hope in the battle against cancer. The oncology segment stands as the leading contributor to the market's growth.

Tissue Engineering Takes Center Stage in Regenerative Medicine

Tissue engineering has solidified its position as a pivotal segment within the regenerative therapies market. This innovative field focuses on the replication and production of tissues and organs for therapeutic purposes. Over the past two decades, tissue engineering has undergone significant evolution, extending its applications beyond traditional tissue repair. It now plays a crucial role in developing physiologically relevant in vitro models, facilitating the translation of new therapeutics into clinical practice. The continued growth and innovation within tissue engineering underscore its central role in the regenerative medicine Analysis.

Global Initiatives to Overcome Therapeutic Challenges

The increasing demand for advanced therapeutic solutions is a major catalyst for the growth of the regenerative therapies market. Government backing, substantial investments in research and development, and the establishment of specialized centers are all contributing to market expansion. These efforts aim to address the rising prevalence of chronic diseases and to provide novel treatments for patients lacking permanent cures. The surge in government initiatives and supportive policies is expected to further accelerate the development and commercialization of regenerative therapies.

Financial and Partnership Challenges for Emerging Firms

Despite the positive outlook for the regenerative therapies market, smaller firms within the industry face considerable hurdles, particularly in securing sufficient financial support. The scarcity of funding options has stalled the progress of numerous promising research projects, leading to the discontinuation of clinical trials. Moreover, the lack of profitable collaborations and licensing agreements with medical device companies has hindered the growth of start-ups specializing in regenerative therapies. These challenges highlight the critical need for increased financial backing and strategic partnerships to sustain the development of innovative therapies.

U.S. Market Maintains Leadership Due to High Cancer Rates

The United States continues to dominate the regenerative therapies market, driven by the high incidence of cancer-related deaths. As one of the leading causes of death in the country, cancer necessitates the adoption of advanced rehabilitation therapies to enhance patient outcomes. The U.S. government's commitment to advancing manufacturing technologies and regulatory standards for regenerative medicine further strengthens the country's market leadership. Ongoing collaboration between regulatory agencies, industry stakeholders, and research institutions is essential for the sustained growth of regenerative therapies in the U.S.

Australia's Strategic Role in Regenerative Medicine

Australia has emerged as a key player in the regenerative therapies market, supported by a robust foundation in research and development. The country's well-established healthcare infrastructure, along with financial incentives for medical research, positions it as an attractive destination for clinical trials and the advancement of regenerative medicine. Australia's dedication to innovation and its focus on developing state-of-the-art manufacturing and cell processing technologies are driving market growth in the region.

India's Growth Fueled by Government Support

India's regenerative therapies market is on the rise, bolstered by strong government support and funding for research and development initiatives. The country's emphasis on homegrown innovation and the formation of national and international collaborations are contributing to the growth of regenerative medicine. The advancement of capabilities in stem cell research, tissue engineering, and gene therapy is setting the stage for a healthcare revolution in India. The establishment of specialized research institutions further emphasizes the government's commitment to advancing regenerative therapies.

Japan's Regulatory Reforms Drive Market Growth

Japan is experiencing significant expansion in its regenerative therapies market, driven by ongoing healthcare reforms and the easing of regulatory barriers. These reforms are aimed at enhancing access to affordable and effective medical treatments for the Japanese population. The government's efforts to accelerate the market entry of regenerative therapies are expected to spur further growth in the coming years. The integration of regenerative medicine into Japan's healthcare system represents a major step forward in addressing chronic diseases and improving patient outcomes.

Competitive Analysis

•AstraZeneca

•GlaxoSmithKline (GSK)

•Bristol-Myers Squibb Company

•Organogenesis Inc.

•Genzyme

•Takara Bio Inc.

•Novartis AG

•Eli Lilly and Company

•NuVasive, Inc.

•Athersys, Inc.

•Mesoblast Ltd

•Cytori Therapeutics Inc.

•3M

Key Segments of Regenerative Therapies Industry Research

By Therapy Types:

•Cell Therapy

oAutologous Cell Therapy

oAllogenic Cell Therapy

•Stem Cell Therapy

oAllogeneic Stem Cell Therapy

oAutologous Stem Cell Therapy

•Tissue engineering

•Gene Therapy

By Application:

•Wound Care

•Musculoskeletal

•Oncology

•Dental

•DMD (Duchenne Muscular Dystrophy)

•Hepatological Diseases

•Inflammatory & Autoimmune Diseases

•Other Therapeutic Applications

By Region:

•North America

•Latin America

•Europe

•South Asia

•East Asia

•Oceania

•Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Regenerative Therapies Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Regenerative Therapies Market Outlook, 2018 – 2031
3.1. Global Regenerative Therapies Market Outlook, By Therapy, Value (US$ Bn), 2018 – 2031
3.1.1. Key Highlights
3.1.1.1. Stem Cell Therapy
3.1.1.1.1. Allogenic Stem Cell Therapy
3.1.1.1.2. Autologous Stem Cell Therapy
3.1.1.2. Cell Therapy
3.1.1.2.1. Autologous Cell Therapy
3.1.1.2.2. Allogenic Cell Therapy
3.1.1.3. Gene Therapy
3.1.1.4. Tissue Engineering
3.2. Global Regenerative Therapies Market Outlook, By Application, Value (US$ Bn), 2018 – 2031
3.2.1. Key Highlights
3.2.1.1. Wound Care
3.2.1.2. Oncology
3.2.1.3. Dental
3.2.1.4. Duchenne Muscular Dystrophy (DMD)
3.2.1.5. Inflammatory & Autoimmune Diseases
3.2.1.6. Hepatological Diseases
3.2.1.7. Others
3.3. Global Regenerative Therapies Market Outlook, by Region, Value (US$ Bn), 2018 – 2031
3.3.1. Key Highlights
3.3.1.1. North America
3.3.1.2. Europe
3.3.1.3. Asia Pacific
3.3.1.4. Latin America
3.3.1.5. Middle East & Africa
4. North America Regenerative Therapies Market Outlook, 2018 – 2031
4.1. North America Regenerative Therapies Market Outlook, By Therapy, Value (US$ Bn), 2018 – 2031
4.1.1. Key Highlights
4.1.1.1. Stem Cell Therapy
4.1.1.1.1. Allogenic Stem Cell Therapy
4.1.1.1.2. Autologous Stem Cell Therapy
4.1.1.2. Cell Therapy
4.1.1.2.1. Autologous Cell Therapy
4.1.1.2.2. Allogenic Cell Therapy
4.1.1.3. Gene Therapy
4.1.1.4. Tissue Engineering
4.2. North America Regenerative Therapies Market Outlook, By Application, Value (US$ Bn), 2018 – 2031
4.2.1. Key Highlights
4.2.1.1. Wound Care
4.2.1.2. Oncology
4.2.1.3. Dental
4.2.1.4. Duchenne Muscular Dystrophy (DMD)
4.2.1.5. Inflammatory & Autoimmune Diseases
4.2.1.6. Hepatological Diseases
4.2.1.7. Others
4.3. North America Regenerative Therapies Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
4.3.1. Key Highlights
4.3.1.1. U.S. Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
4.3.1.2. U.S. Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
4.3.1.3. Canada Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
4.3.1.4. Canada Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
4.3.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Regenerative Therapies Market Outlook, 2018 – 2031
5.1. Europe Regenerative Therapies Market Outlook, By Therapy, Value (US$ Bn), 2018 – 2031
5.1.1. Key Highlights
5.1.1.1. Stem Cell Therapy
5.1.1.1.1. Allogenic Stem Cell Therapy
5.1.1.1.2. Autologous Stem Cell Therapy
5.1.1.2. Cell Therapy
5.1.1.2.1. Autologous Cell Therapy
5.1.1.2.2. Allogenic Cell Therapy
5.1.1.3. Gene Therapy
5.1.1.4. Tissue Engineering
5.2. Europe Regenerative Therapies Market Outlook, By Application, Value (US$ Bn), 2018 – 2031
5.2.1. Key Highlights
5.2.1.1. Wound Care
5.2.1.2. Oncology
5.2.1.3. Dental
5.2.1.4. Duchenne Muscular Dystrophy (DMD)
5.2.1.5. Inflammatory & Autoimmune Diseases
5.2.1.6. Hepatological Diseases
5.2.1.7. Others
5.3. Europe Regenerative Therapies Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
5.3.1. Key Highlights
5.3.1.1. Germany Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
5.3.1.2. Germany Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
5.3.1.3. U.K. Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
5.3.1.4. U.K. Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
5.3.1.5. France Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
5.3.1.6. France Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
5.3.1.7. Italy Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
5.3.1.8. Italy Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
5.3.1.9. Turkey Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
5.3.1.10. Turkey Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
5.3.1.11. Russia Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
5.3.1.12. Russia Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
5.3.1.13. Rest of Europe Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
5.3.1.14. Rest of Europe Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
5.3.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Regenerative Therapies Market Outlook, 2018 – 2031
6.1. Asia Pacific Regenerative Therapies Market Outlook, By Therapy, Value (US$ Bn), 2018 – 2031
6.1.1. Key Highlights
6.1.1.1. Stem Cell Therapy
6.1.1.1.1. Allogenic Stem Cell Therapy
6.1.1.1.2. Autologous Stem Cell Therapy
6.1.1.2. Cell Therapy
6.1.1.2.1. Autologous Cell Therapy
6.1.1.2.2. Allogenic Cell Therapy
6.1.1.3. Gene Therapy
6.1.1.4. Tissue Engineering
6.2. Asia Pacific Regenerative Therapies Market Outlook, By Application, Value (US$ Bn), 2018 – 2031
6.2.1. Key Highlights
6.2.1.1. Wound Care
6.2.1.2. Oncology
6.2.1.3. Dental
6.2.1.4. Duchenne Muscular Dystrophy (DMD)
6.2.1.5. Inflammatory & Autoimmune Diseases
6.2.1.6. Hepatological Diseases
6.2.1.7. Others
6.3. Asia Pacific Regenerative Therapies Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
6.3.1. Key Highlights
6.3.1.1. China Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
6.3.1.2. China Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
6.3.1.3. Japan Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
6.3.1.4. Japan Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
6.3.1.5. South Korea Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
6.3.1.6. South Korea Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
6.3.1.7. India Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
6.3.1.8. India Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
6.3.1.9. Southeast Asia Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
6.3.1.10. Southeast Asia Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
6.3.1.11. Rest of Asia Pacific Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
6.3.1.12. Rest of Asia Pacific Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
6.3.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Regenerative Therapies Market Outlook, 2018 – 2031
7.1. Latin America Regenerative Therapies Market Outlook, By Therapy, Value (US$ Bn), 2018 – 2031
7.1.1. Key Highlights
7.1.1.1. Stem Cell Therapy
7.1.1.1.1. Allogenic Stem Cell Therapy
7.1.1.1.2. Autologous Stem Cell Therapy
7.1.1.2. Cell Therapy
7.1.1.2.1. Autologous Cell Therapy
7.1.1.2.2. Allogenic Cell Therapy
7.1.1.3. Gene Therapy
7.1.1.4. Tissue Engineering
7.2. Latin America Regenerative Therapies Market Outlook, By Application, Value (US$ Bn), 2018 – 2031
7.2.1. Key Highlights
7.2.1.1. Wound Care
7.2.1.2. Oncology
7.2.1.3. Dental
7.2.1.4. Duchenne Muscular Dystrophy (DMD)
7.2.1.5. Inflammatory & Autoimmune Diseases
7.2.1.6. Hepatological Diseases
7.2.1.7. Others
7.3. Latin America Regenerative Therapies Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
7.3.1. Key Highlights
7.3.1.1. Brazil Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
7.3.1.2. Brazil Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
7.3.1.3. Mexico Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
7.3.1.4. Mexico Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
7.3.1.5. Argentina Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
7.3.1.6. Argentina Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
7.3.1.7. Rest of Latin America Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
7.3.1.8. Rest of Latin America Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
7.3.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Regenerative Therapies Market Outlook, 2018 – 2031
8.1. Middle East & Africa Regenerative Therapies Market Outlook, By Therapy, Value (US$ Bn), 2018 – 2031
8.1.1. Key Highlights
8.1.1.1. Stem Cell Therapy
8.1.1.1.1. Allogenic Stem Cell Therapy
8.1.1.1.2. Autologous Stem Cell Therapy
8.1.1.2. Cell Therapy
8.1.1.2.1. Autologous Cell Therapy
8.1.1.2.2. Allogenic Cell Therapy
8.1.1.3. Gene Therapy
8.1.1.4. Tissue Engineering
8.2. Middle East & Africa Regenerative Therapies Market Outlook, By Application, Value (US$ Bn), 2018 – 2031
8.2.1. Key Highlights
8.2.1.1. Wound Care
8.2.1.2. Oncology
8.2.1.3. Dental
8.2.1.4. Duchenne Muscular Dystrophy (DMD)
8.2.1.5. Inflammatory & Autoimmune Diseases
8.2.1.6. Hepatological Diseases
8.2.1.7. Others
8.3. Middle East & Africa Regenerative Therapies Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
8.3.1. Key Highlights
8.3.1.1. GCC Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
8.3.1.2. GCC Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
8.3.1.3. South Africa Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
8.3.1.4. South Africa Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
8.3.1.5. Egypt Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
8.3.1.6. Egypt Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
8.3.1.7. Nigeria Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
8.3.1.8. Nigeria Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
8.3.1.9. Rest of Middle East & Africa Regenerative Therapies Market By Therapy, Value (US$ Bn), 2018 – 2031
8.3.1.10. Rest of Middle East & Africa Regenerative Therapies Market By Application, Value (US$ Bn), 2018 – 2031
8.3.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Market Share Analysis, 2022
9.2. Competitive Dashboard
9.3. Company Profiles
9.3.1. AstraZeneca plc
9.3.1.1. Company Overview
9.3.1.2. Product Portfolio
9.3.1.3. Financial Overview
9.3.1.4. Business Strategies and Development
9.3.2. GSK
9.3.2.1. Company Overview
9.3.2.2. Product Portfolio
9.3.2.3. Financial Overview
9.3.2.4. Business Strategies and Development
9.3.3. Bristol-Myers Squibb
9.3.3.1. Company Overview
9.3.3.2. Product Portfolio
9.3.3.3. Financial Overview
9.3.3.4. Business Strategies and Development
9.3.4. Genzyme
9.3.4.1. Company Overview
9.3.4.2. Product Portfolio
9.3.4.3. Financial Overview
9.3.4.4. Business Strategies and Development
9.3.5. Takara Bio Inc.
9.3.5.1. Company Overview
9.3.5.2. Product Portfolio
9.3.5.3. Financial Overview
9.3.5.4. Business Strategies and Development
9.3.6. Novartis AG
9.3.6.1. Company Overview
9.3.6.2. Product Portfolio
9.3.6.3. Financial Overview
9.3.6.4. Business Strategies and Development
9.3.7. Eli Lilly and Company
9.3.7.1. Company Overview
9.3.7.2. Product Portfolio
9.3.7.3. Financial Overview
9.3.7.4. Business Strategies and Development
9.3.8. Cytori Therapeutics Inc.
9.3.8.1. Company Overview
9.3.8.2. Product Portfolio
9.3.8.3. Financial Overview
9.3.8.4. Business Strategies and Development
9.3.9. NuVasive, Inc.
9.3.9.1. Company Overview
9.3.9.2. Product Portfolio
9.3.9.3. Financial Overview
9.3.9.4. Business Strategies and Development
9.3.10. Organogenesis, Inc.
9.3.10.1. Company Overview
9.3.10.2. Product Portfolio
9.3.10.3. Financial Overview
9.3.10.4. Business Strategies and Development
9.3.11. Mesoblast Ltd.
9.3.11.1. Company Overview
9.3.11.2. Product Portfolio
9.3.11.3. Financial Overview
9.3.11.4. Business Strategies and Development
9.3.12. Athersys, Inc.
9.3.12.1. Company Overview
9.3.12.2. Product Portfolio
9.3.12.3. Financial Overview
9.3.12.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations